Authors
Latest:
Defining the Role of Perioperative Therapy Across Lung Cancer SubtypesPatients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Latest:
How to Treat Metastatic Malignant Triton Tumor in an AdolescentA systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Latest:
Expert Commentary on the Product Profile of Umbralisib for LymphomaIn an interview with ONCOLOGY®, Douglas Braun, CSP, PharmD, RPh, offers a comprehensive review of real-world treatment considerations of umbralisib as therapy for patients with previously treated follicular and marginal zone lymphoma.
Latest:
Next Steps in Adoption of Maintenance Therapy with Immune Checkpoint InhibitorsDrs. Gupta and Brown share their thoughts on the next steps that can aid in uptake of maintenance therapy in different tumor types.
Latest:
Immune Modulation in Sarcoma: Targeting the Tumor MicroenvironmentExplore the latest advancements in sarcoma immunotherapy, focusing on tumor microenvironment modulation and innovative treatment strategies for improved patient outcomes.
Latest:
Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer OrganizationsAlthough female representation for National Comprehensive Cancer Network guidelines has increased to at least 50%, participation in guideline panels across all organizations is still less than 30%.
Latest:
Sylvie Bonvalot, MD, PhD, Discusses Selecting Patients With Locally Advanced Sarcoma for Pre and Postoperative TreatmentCancerNetwork® sat down with Sylvie Bonvalot, MD, PhD, at the 2021 ASCO Annual Meeting to talk about treatment options for high-grade or grade II sarcoma.
Latest:
Navigating the Difficulties of Nutrition During Cancer Care as a Nurse“Food is powerful, and [patients] need fuel,” said Claudia Aguilar Clancy, RN, FNP-C, about ensuring patients receive the nutrition they require during cancer treatment.
Latest:
Elucidating Noninvasive Radiosurgery Advancements in CNS TumorsA dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.
Latest:
Managing Hematological Toxicities Associated with Bispecifics in MMExperts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Patient Case Presentation: Patient on ESA for First-Line Therapy and Not Receiving a Marked Response—What Do You Do Next, and Why?Panelists discuss management strategies for a patient with low-risk myelodysplastic syndrome with erythropoiesis-stimulating agent (ESA) failure, weighing options between initiating luspatercept or escalating ESA dosage while emphasizing the need for thorough evaluation of reversible causes before advancing therapy.
Latest:
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid LeukemiaInvestigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Latest:
AI to Accelerate the Future of Pancreatic Cancer Prevention/CareMedical use of AI increases every day, and in the future, will be exponentially greater and many forms of treatment will be improved, according to Russell C. Langan, MD, FACS, FSSO.
Latest:
Navigating AE Management for Cellular Therapy Across Hematologic CancersA panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
